Rosiglitazone appears to activate PPAGR and has an anti-inflammatory effect that down-regulates nuclear factor kappa-B (NFκB) level[49,50]; Sulfasalazine(SASP, DB00795), another PPAGR-targeted drug, for which the current indication is inflammatory bowel disease and rheumatoid arthritis, is also useful in restricting lymphoma growth and for therapy of prostate cancers by inhibiting cystine transporter[51,52]; Telmisartan (DB00966) is effective for prevention and treatment of prostate cancer[53]. The gene discussed is NFKB1; the disease is inflammatory bowel disease.